Tobira Therapeutics Inc buy Quitte
Start price
27.08.15
/
50%
€12.18
Target price
21.09.15
€12.50
Performance (%)
2.93%
End price
21.09.15
€12.54
Summary
This prediction ended on 21.09.15 with a price of €12.54. The BUY prediction by Quitte finished with a performance of 2.93%. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Tobira Therapeutics Inc | - | - | - | - |
| iShares Core DAX® | 1.001% | -1.218% | 13.263% | 60.023% |
| iShares Nasdaq 100 | -1.447% | -4.597% | 0.414% | 85.321% |
| iShares Nikkei 225® | 8.406% | 8.425% | 27.328% | 61.038% |
| iShares S&P 500 | -0.226% | -2.451% | 0.167% | 57.738% |
Comments by Quitte for this prediction
In the thread Tobira Therapeutics Inc diskutieren
aussichtsreich
Tobira Therapeutics Inc. (TBRA) hat eine Phase IIa-Studie von Cenicriviroc initiiert.
Übergewichtige Erwachsene mit Prädiabetes oder Diabetes sowie Fettlebererkrankungen halte ich für einen Riesen-Markt, wenn das Medikament Erfolg hat.
Stopped prediction by Quitte for Tobira Therapeutics Inc
Tobira Therapeutics Inc
Start price
Target price
Perf. (%)
€10.82
23.06.16
23.06.16
€11.73
02.12.16
02.12.16
250.75%
02.12.16
02.12.16
Tobira Therapeutics Inc
Start price
Target price
Perf. (%)
€8.66
21.12.15
21.12.15
€9.92
21.06.16
21.06.16
18.02%
21.06.16
21.06.16